Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sold first order @8.70 from 5.4s then re entered 6.80s which I Will dump tomorrow @20$
This is just day 1 of a massive low float run up before offering. We have seen it plenty of Times in the past. This was 7 when I called for 40$. It has already almost doubled from then.
$40 a share, Don't tease me like that Makk1' I'm back in @ $10.50 and watching closely to bail if I need to. I might just close my position and wait until after hours to re-enter for more quick cash. lol.
Halts are nerve wracking, no doubt...a little less so for legitimate stocks. I came painfully close to getting caught in a suspension about a month ago with H*NT, took a few days off after that one...
it halted a couple of times today, but each time it open up very nice. To all the shorts whom welcome shareholders as Bagholders when share price drop from $9 down to 6.75 Please step up and raise your hands if you need to know where the Shorts Margin Call line is. It is that long line which wrap around your broker's office. hehee lol
Just kidding. lol.
Man I get nervous when it halts.... Sometimes comes back and goes south, but I have a feeling this one gonna keep on plugging along
GLTA
wow, beauty of a day....the 1 for 18 RS less than a month ago holders hopefully took their exit...low float, I imagine some unhappy shorts, could do $14+...
GOOOOO $ABIO! WEEEEE!!! :) I was a bagholder. Glad I hung on through the RS :) And I'm still going to hold!
700,000 dollars on the bid
Shorts toast
$20 premarket tomorrow, looks like it could be breaking yearly high.
One heck of a squeeze. Higher we go on commencement weeeeee
It needs to run to 40$ IMO. Once there they Will do offering
Come on ARCA biopharma let's run like Bio Path Holding (BPTH) did in March all the way from $2 to $73.
in at $5.25 on opening out @ $8.75 hoping that it would had a strong run to $10 with a 1 million float and a very small out standing count. Waiting @ $6.80 to get back in. Nice if it did what ZSAN and BPTH did 2 months ago. BPTH ran to $73 with a low float and small out standing count in 2 days.after r/s. Same could happen here.
Yeah unfortunately I can only average down and im not going to on this one. Just going to wait for news on phase results. Glt you.
Otherwise it may be a good entry for swing trade 3,50-4$... On close watch
This looks like a nice short term swing trade. A least keep a close eye on it. Love the pattern, and the split reduces the market cap to about the amount of cash on hand give or take
I contacted them via email and suggested they really ought to put out some news with this RS. I'll let y'all know if I get an answer.
Yes and with no good news to go with it! That is so dumb! It's kind of a no-brainer I think from a companies perspective: "Hey....on the day of the RS...let's put out a good PR about what we are accomplishing to help the shareholders and price rise." And we get nothing! I'm so mad! Grrrrr
$ABIO Hey lets buy and get to $1 before a RS. lol
Also still "caught" here although not invested right now. Rode the swings before, the next one is going to happen soon imo
GLTY, added a person mark
Ok. What's the deal here. Is this thing supposed to split soon? Grrr.....I got screwed big time on this one and bought in .60's/.85's. Best news we could have would be FDA approval of "something." But guess they are still in phase 3 trials. Everything looks encouraging in the trial news so far.... $ABIO
ABIO I'm in!! Looking for a nice reversal here!! MBD
10 K Press Release. Positive cash flow till end of 2019.
Some nice trading this week, but 3rd RS needs to occur by 4/8/19 if they don't go 10 consecutive days over $1 before then, RS already approved...trade accordingly. Might catch some scalps around 40-42 to 46-49 today.
Jep, may be time to buy in again. Astonishing it went down nearly to pre PR level. Gonna buy late today or on Monday.
Got a coupe blocks looking for research report updated one of these days.
I hear ya..Not done Yet..LoL..
* * $ABIO Video Chart 02-20-2019 * *
Link to Video - click here to watch the technical chart video
Very difficult in a surrounding like ihub where everyone knows best and nobody would even admit losses...
Took my +100% profits,now in CVM. P3 results out soon.
Sold at .95/share. I will get back in after dilution and a possoble reverse split
I'd rather help people cut losses if possible by posting my predictions. We're all trying to win together my dude
Followers
|
104
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2418
|
Created
|
12/11/06
|
Type
|
Free
|
Moderators |
***These patients experienced a 74% (p = 0.0003) reduction in risk of AF versus no detectable reduction in patients who had alternative genotypes (beta1389 Gly carriers; 53% of the patients) who had received placebo. The Company believes this data supports the potential ability of Gencaro to prevent AF in patients who have the genotype the Company believes responds most favorably to Gencaro.
The Science:
GENETIC-AF Clinical Trial
GENETIC-AF is planned as a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing Gencaro to metoprolol CR/XL for prevention of AF in patients with heart failure and reduced left ventricular ejection fraction (HFREF). ARCA plans to enroll only patients with the genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the Company plans to initiate it as a Phase 2B study in approximately 200 patients and then, depending on the results of an interim analysis by the trial Data Safety Monitoring Board (DSMB), expand the trial to a Phase 3 study by enrolling an estimated additional 420 patients.
Under the collaboration with Medtronic, ARCA plans to conduct a substudy that will include continuous monitoring of the cardiac rhythms of all 200 patients enrolled during the Phase 2B portion of GENETIC-AF. Each patient will have heart rhythm monitoring via a Medtronic device, either a previously implanted cardiac resynchronization or defibrillation device, or a previously or newly inserted Reveal® loop recorder. The collaboration substudy will measure AF burden, defined as a patient’s actual time in AF regardless of symptoms. For the DSMB interim analysis, AF burden and the primary endpoint of the study, time to recurrence of symptomatic AF after electrical cardioversion, or death, will be reviewed by the DSMB to determine if there is sufficient potential for a statistically significant efficacy signal to be determined for all patients enrolled in the Phase 2B/3 study.
Gencaro Data in Atrial Fibrillation
Clinical data analysis from a post-hoc review of patient forms from the from BEST trial, a Phase 3 trial in 2,708 patients with advanced heart failure, indicate that Gencaro may have a potentially enhanced and pharmacogenetically-influenced effect in reducing and preventing AF. In that trial, patients in the Gencaro arm had a reduction in the risk of new onset AF time to event compared to patients in the placebo arm of 41% (AF measured as an adverse event/serious adverse event or as detected on surveillance ECGs, time to event analysis, p = 0.0004). In a 1,040 patient DNA substudy of BEST, Gencaro exhibited potential pharmacogenetic enhancement and differentiation for AF prevention in patients with a specific genotype (beta1389 arginine homozygous (Arg/Arg) adrenergic receptor (AR); approximately 47% of the patients). These patients experienced a 74% (p = 0.0003) reduction in risk of AF versus no detectable reduction in patients who had alternative genotypes (beta1389 Gly carriers; 53% of the patients) who had received placebo. The Company believes this data supports the potential ability of Gencaro to prevent AF in patients who have the genotype the Company believes responds most favorably to Gencaro.
In prior placebo controlled trials of beta blockers in chronic HFREF, most studies comparing beta-blockers to placebo have detected a positive signal for prevention of AF, with an event rate reduction averaging approximately 27%, although AF had not been a pre-specified primary or secondary endpoint in these studies. Currently, no beta-blocker has been approved by the U.S. Food and Drug Administration for the prevention of
AF in heart failure patients.
Gencaro™ [Bucindolol Hydrochloride]
ARCA is currently developing Gencaro™ (tradename pending FDA approval) (bucindolol hydrochloride) for the prevention of atrial fibrillation and the treatment of chronic heart failure. Gencaro™ is a pharmacologically unique beta-blocker and mild vasodilator. Gencaro™ is considered part of the beta-blocker class because of its property of blocking beta-1 as well as beta-2 receptors in the heart, preventing these receptors from binding with other molecules that would otherwise activate the receptor. Because of its mild vasodilator effects, the Company believes Gencaro™ is well-tolerated in patients with advanced HF. ARCA has identified common genetic variations, or genetic markers, that it believes predict patient response to Gencaro™.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |